	US 12,239,714 B2
	Phosphatidylserine-binding conjugates
Takumi Kawabe, Numazu (JP); Takuji Sato, Numazu (JP); Tatsuya Kibe, Numazu (JP); Toshiyuki Hibino, Numazu (JP); Jonathan M. Friedman, Numazu (JP); Sayaka Yamamoto, Numazu (JP); and Chikako Suda, Numazu (JP)
Assigned to CANBAS CO., LTD., Numazu (JP)
Filed by CANBAS CO., LTD., Numazu (JP)
Filed on Dec. 28, 2022, as Appl. No. 18/090,259.
Claims priority of provisional application 63/295,462, filed on Dec. 30, 2021.
Prior Publication US 2023/0270869 A1, Aug. 31, 2023
Int. Cl. A61K 47/64 (2017.01); A61K 31/165 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)

CPC A61K 47/64 (2017.08) [A61K 31/165 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)]

22 Claims

1. A phosphatidylserine-binding (PS-binding) conjugate, wherein the conjugate comprises more than two PS-binding peptide sequences selected from the group consisting of: LIKKPF (SEQ ID NO:1), PGDLSR (SEQ ID NO: 2), CLIKKPF (SEQ ID NO:3), CPGDLSR (SEQ ID NO:4), FNFRLKAGAKIRFG (SEQ ID NO:5), FXFXLKXXXKXR (SEQ ID NO:6), TLVSSL (SEQ ID NO:7), CLSYYPSYC (SEQ ID NO:8), GEGKGGr (SEQ ID NO:9), gegkggr (SEQ ID NO:10), GEGr (SEQ ID NO:11), gegr (SEQ ID NO:12), GE, ge, RGEGR (SEQ ID NO:13), rgegr (SEQ ID NO:14), and Cyclo(RKKWFGC) (SEQ ID NO:15); wherein a capital letter indicates a L-amino acid, and a non-capitalized letter indicates a D-amino acid, and wherein “X” represents any L-amino acid, and at least one Toll-like Receptor binding (TLR-binding) domain.